HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Second-line levofloxacin-based triple therapy's efficiency for Helicobacter pylori eradication in patients with peptic ulcer.

AbstractOBJECTIVES:
First-line standard eradication efficacy with lansoprazole, amoxicillin and clarithromycin regressed over 10 years. The aim of this study was to evaluate the efficacy and tolerability of a levofloxacin-based regimen in patients with peptic ulcer after failure of the standard first-line H.pylori eradication therapy in a country with a high rate of infection.
METHODS:
A total of 91 peptic ulcer patients who were diagnosed H.pylori positive proven by rapid urease test and histology between November 2005 to March 2008 were given lansoprazole 30 mg bid, amoxicillin 1 g bid and clarithromycin 500 mg bid (LAC) for 14 days. After three months from the first line eradication treatment omeprazole 20 mg bid, levofloxacin 500 mg bid, amoxicillin 1 g bid (OLA) 7 day treatment regimen was recommended as a second-line therapy for 37 patients who failed at first-line standard triple therapy.
RESULTS:
Eradication rates for LAC regimen were found to be 57.14% (52/91) for intention to treat and 58.42% (52/89) for per protocol analysis. Eradication rates for OLA regimen were found to be 37.83% (14/37) for ITT and 41.17% (14/34) for PP analysis.
CONCLUSION:
OLA regimen eradication rate was successful only in 40% of patients who failed in the first-line eradication. New eradication treatment strategies must be performed, at least in Turkey.
AuthorsFatih Ermis, Filiz Akyuz, Ahmet Uyanikoglu, Ramazan Kurt, Binnur Pinarbasi, Hasan Nazik, Sabahattin Kaymakoglu, Zeynel Mungan
JournalSouthern medical journal (South Med J) Vol. 104 Issue 8 Pg. 579-83 (Aug 2011) ISSN: 1541-8243 [Electronic] United States
PMID21886067 (Publication Type: Journal Article, Randomized Controlled Trial)
Chemical References
  • Anti-Bacterial Agents
  • Anti-Ulcer Agents
  • Levofloxacin
  • Amoxicillin
  • Ofloxacin
  • Omeprazole
Topics
  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Amoxicillin (adverse effects, therapeutic use)
  • Anti-Bacterial Agents (therapeutic use)
  • Anti-Ulcer Agents (therapeutic use)
  • Drug Therapy, Combination
  • Female
  • Helicobacter Infections (drug therapy, microbiology)
  • Helicobacter pylori
  • Humans
  • Intention to Treat Analysis
  • Levofloxacin
  • Male
  • Middle Aged
  • Ofloxacin (adverse effects, therapeutic use)
  • Omeprazole (adverse effects, therapeutic use)
  • Peptic Ulcer (drug therapy, microbiology)
  • Treatment Outcome
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: